Table 1.
Baseline Characteristics of the 2 Groups
| Variables | N | BAS (n=699) | ATG (n=1612) | P Value |
|---|---|---|---|---|
| Recipient | ||||
| Age, y | 2311 | 8.6±6.3 | 6.1±6.2 | <0.001 |
| Female sex | 2311 | 363 (51.9) | 756 (46.9) | 0.026 |
| Weight, kg | 2305 | 30.8±22.0 | 24.8±23.0 | <0.001 |
| Height, cm | 2307 | 121.0±39.7 | 105.6±42.9 | <0.001 |
| Diagnosis | ||||
| Coronary artery disease | 16 | 3 (0.4) | 13 (0.8) | <0.001 |
| Cardiomyopathy | 949 | 287 (41.1) | 662 (41.1) | |
| Congenital | 868 | 168 (24.0) | 700 (43.4) | |
| Retransplant because of graft failure | 127 | 26 (3.7) | 101 (6.3) | |
| Heart valve disease | 3 | 0 (0) | 3 (0.2) | |
| Miscellaneous | 348 | 215 (30.8) | 133 (8.3) | |
| Blood group | ||||
| A | 2311 | 254 (36.3) | 623 (38.7) | 0.293 |
| AB | 2311 | 35 (5.0) | 57 (3.5) | 0.097 |
| B | 2311 | 95 (13.6) | 206 (12.8) | 0.594 |
| O | 2311 | 315 (45.1) | 726 (45.0) | 0.990 |
| Antiarrhythmics before transpl | 603 | 23 (21.1) | 81 (16.4) | 0.239 |
| Inotrop support before transpl | 2311 | 261 (37.3) | 779 (48.3) | <0.001 |
| Implantable defibrillator | 1963 | 52 (11.0) | 118 (7.9) | 0.040 |
| Obstructive pulmonary disease | 612 | 2 (1.8) | 0 (0) | 0.034 |
| Diabetes (insulin‐treated) | 2301 | 57 (8.3) | 24 (1.5) | <0.001 |
| Hypertension | 698 | 20 (12.2) | 65 (12.2) | 0.994 |
| CMV status | 1949 | 274 (45.9) | 608 (45.0) | 0.705 |
| Dialysis pretransplant | 2307 | 22 (3.2) | 49 (3.0) | 0.885 |
| Oxygen consumption at exercise | 70 | 14.3±4.6 | 13.7±6.8 | 0.767 |
| Medical condition at transplant | ||||
| Home | 805 | 258 (36.9) | 547 (33.9) | 0.139 |
| Hospital | 400 | 137 (19.6) | 263 (16.3) | |
| Intensive care unit | 1106 | 304 (43.5) | 802 (49.8) | |
| Mechanical ventilation | 2311 | 125 (17.9) | 314 (19.5) | 0.369 |
| ECMO | 2311 | 29 (4.2) | 106 (6.6) | 0.022 |
| Ventricular assist device | 2162 | 81 (12.4) | 204 (13.6) | 0.449 |
| Creatinine most recent, μmol/L | 2258 | 53.7±64.6 | 51.5±47.4 | 0.357 |
| PVR (WU) | 678 | 4.2±3.7 | 4.2±3.9 | 0.962 |
| Previous blood transfusion | 1254 | 235 (83.3) | 831 (85.5) | 0.371 |
| Previous transplant | 2308 | 34 (4.9) | 109 (6.8) | 0.082 |
| PRA class 1 | 1679 | 4.7±14.4 | 9.5±22.9 | <0.001 |
| PRA class 2 | 1602 | 4.9±16.1 | 10.6±25.8 | <0.001 |
| Donor | ||||
| Age, y | 2311 | 11.9±11.2 | 8.2±9.3 | <0.001 |
| Female sex | 2311 | 306 (43.8) | 711 (44.1) | 0.883 |
| Weight, kg | 1579 | 50.1±24.5 | 44.2±24.8 | <0.001 |
| Height, cm | 1566 | 147.9±28.3 | 140.6±31.7 | <0.001 |
| Blood group | ||||
| A | 2311 | 194 (27.8) | 523 (32.4) | 0.025 |
| AB | 2311 | 6 (0.9) | 29 (1.8) | 0.097 |
| B | 2311 | 52 (7.4) | 143 (8.9) | 0.255 |
| O | 2311 | 447 (64.0) | 917 (56.9) | 0.002 |
| Diabetes | 2305 | 9 (1.3) | 12 (0.8) | 0.234 |
| CMV status | 2288 | 376 (54.8) | 855 (53.4) | 0.527 |
| Hypertension | 2303 | 24 (3.4) | 23 (1.4) | 0.002 |
| Ischemic time, minute | 2244 | 225 (181–297) | 226 (184–273) | 0.254 |
Qualitative data are expressed as n (%) and quantitative data as mean±SD or median (interquartile range), as appropriate. ATG indicates anti‐thymocyte globulin; BAS, basiliximab; CMV, cytomegalovirus; ECMO, extracorporeal membrane oxygenation; N, number of transplants with nonmissing values; n, total number of transplants; PRA, panel‐reactive antibodies; Previous transplant, previous kidney, liver, pancreas, pancreas islet cells, heart, lung, intestine, and/or bone marrow transplant; PVR, pulmonary vascular resistance; Transpl, transplant; WU, Wood units.